Enobia Pharma
2901, Rachel Street East, Suite 23
Montreal
Quebec
Canada
Tel: 514-596-2901
Fax: 514-596-2749
Website: http://www.enobia.com/
25 articles about Enobia Pharma
-
Alexion Pharmaceuticals Inc. Completes Acquisition of Enobia Pharma
2/7/2012
-
Alexion Pharmaceuticals Inc. to Pay $1 Billion for Enobia Pharma
12/29/2011
-
Alexion Pharmaceuticals Inc. to Host Conference Call This Morning to Discuss Company’s Proposed Acquisition of Enobia Pharma
12/29/2011
-
Enobia Pharma Raises US $40 Million
8/10/2011
-
Lonza Inc. Signs Commercial Manufacturing Deal with Enobia Pharma for Orphan Drug Candidate
3/15/2011
-
Enobia Pharma Announces Completion of Enrollment in Third Phase II Hypophosphatasia Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
2/24/2011
-
Enobia Pharma Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
1/11/2011
-
Enobia Pharma Reports Positive Results For Phase II Trial of ENB-0040 in Juvenile Hypophosphatasia
9/24/2010
-
Enobia Pharma Provides Update on Progress With ENB-0040, a Bone-Targeted Enzyme Replacement Therapy for Hypophosphatasia
9/8/2010
-
Enobia Pharma: ENB-0040, a Bone Targeted Enzyme Replacement Therapy, Shows Promise in Children with Hypophosphatasia
6/21/2010
-
Enobia Pharma Presents Results from Hypophosphatasia Impact Patient Survey Presentations at ACMG Annual Meeting Spotlight Clinical Progress and Documented Burden of Illness in Hypophosphatasia
3/30/2010
-
Enobia Pharma Expands Clinical Program for ENB-0040, a Bone-Targeted Enzyme Replacement Therapy for Hypophosphatasia
11/3/2009
-
Enobia Pharma Announces Positive Clinical Results With ENB-0040, a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia
9/14/2009
-
Enobia Pharma Raises $50 Million from Current Investors in Series C Financing
8/10/2009
-
Enobia Pharma Announces Positive Interim Clinical Results With ENB-0040
6/11/2009
-
Enobia Pharma's ENB-0040 Receives FDA Fast Track Designation
5/19/2009
-
Enobia Pharma Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia
3/3/2009
-
Enobia Pharma Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
12/1/2008
-
Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
9/22/2008
-
Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
9/19/2008